___

• Soydan S., Veziroglu F., Araz K. Bifosfonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteo- nekrozun Patogenezi ve Tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi. 33:61-68, 2009.
• Fleisch H. Development of bisphosphonates. Bre- ast Cancer Res. 4:30-34, 2002
• Yıldız N., Alpay H. Use of Biphosphonates in Pe- diatric Nephrology Biphosphonates in Pediatric. Turkish Nephrology, Dialysis and Transplantation Journal. 20:132-141, 2011
• Ruggiero S., Dodson TB., Assael LA., Landesberg R., Marx RE., Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Pa- per on Bisphosphonate-Related Osteonecrosis of the Jaw. Aust. Endod. J. 35:119-130, 2009
• Zafersoy Z., Kahraman S. Kemik Metastazı Yap- mış Prostat Kanseri Tedavisinde Kullanılan Bifos- fonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteonekroz: Vaka Raporu Ve Literatür Derleme- si. Atatürk Üniv. Diş. Hek. Fak. Derg. 18:105- 110, 2008.
• Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., Clézardin P. Bisp- hosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538-6544, 2002.
• Giuliani N., Pedrazzoni M., Passeri G., Giraso- le G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol. 27:38-41,1998.
• Watts N. Treatment of osteoporosis with bisp- hosphonates. Endocrinol. Metab. Clin. North Am. 27:419-439, 1998.
• Tuncer B. Bifosfonatlar ve Diş Hekimliği. SÜ Diş- hek. Fak. Derg. 16:57-60, 2007.
• Woo SB., et al. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144:753–761, 2006.
• Scoletta M.,Arduino PG., Dalmasso P., Broccolet- ti R., Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg. Oral Med. Oral Radiol. Endod. 110:46-53, 2010.
• Ruggiero SL.,Mehrotra B., Rosenberg TJ., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62:527-534, 2004.
• Almăşan HA., Băciuţ M., Rotaru H., Bran S, Almăşan O.C., Băciuţ G. Osteonecrosis of the jaws asso- ciated with the use of bisphosphonates Discus- sion over 52 cases. Rom. J. Morphol. Embryol. 52:1233–1241, 2011.
• Tanvetyanon T., Stiff PJ. Management of the ad- verse effects associated with intravenous bisp- hosphonate. Annals of Oncology. 17: 897–907, 2006.
• Rizzoli R., Burlet N., Cahall D, Delmas PD., Erik- sen EF., Felsenberg D., Grbic J., Jontell M., Lan- desberg R., Laslop A., Wollenhaupt M., Papa- poulos S., Sezer O., Sprafka M., Reginster JY. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 42:841-847, 2008.
• Marx RE. Oral and intravenous bisphosphonate- induced osteonecrosis of the jaws: history, eti- logy, prevention, and treatment. Ouintessence Publishing Co, 2012, 45-86.
• Cetiner S., Sucak G., Kahraman S., Akı SZ., Ko- cakahyaoglu B., Gultekin SB., Cetiner M., Haz- nedar R. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J. Bone Miner. Metab. 27:435-443, 2009.
• O’Ryan FS., Khoury S., Liao W., Han MM., Hui RL., Baer D., Martin D., Liberty D., Lo JC. Intra- venous bisph osphonate related osteonecrosis of the jaws; bone scintigraphy as an early indicator. J. Oral Maxillofac. Surg. 67:1363-1372, 2009.
• Lazarovici TS., Mesilaty-Gross S., Vered I., Pari- ente C., Kanety H., Givol N., Yahalom R., Taic- her S., Yarom N. Serologic bone markers for pre- dicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J. Oral Maxillofac. Surg. 68:2241-2247, 2010.
• Michael A., James R. The treatment of bisphosp- honateassociated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. JADA. 138:971-977, 2007.
• Cicciù M., Herford A.S., Juodžbalys G., Stoffella E. Recombinant human bone morphogenetic pro- tein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J. Craniofac. Surg. 23:784-788, 2012.
• Curi M., Cossolin G.S., Koga D.H., Zardetto C., Christianini S., Feher O., Cardoso C.L., dos San- tos M.O. Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologo- us platelet-rich plasma. J. Oral Maxillofac. Surg. 69:2465-2472, 2011.
• Atalay B., Yalcin S., Emes Y., Aktas I., Aybar B., Issever H., Mandel N.M., Cetin O., Oncu B. Bisphosphonate-related osteonecrosis: laser- assisted surgical treatment or conventional sur- gery. Lasers Med. Sci. 26:815-823, 2011.
• Epstein M., Wicknick F.W., Epstein J.B., Berenson J.R., Gorsky M. Management of bisphosphonate- associated osteonecrosis: pentoxifylline and to- copherol in addition to antimicrobial therapy. An initial case series. Oral Surg. Oral Med. Oral Pat- hol. Oral Radiol. Endod. 110:593-596, 2010.
• Erkan M., Bilgi O., Mutluoglu M., Uzun G. Bisphosphonate-Related Osteonecrosis of the Jaw in Cancer Patients and Hyperbaric Oxygen The- rapy. J. Pancreas. 10:579-580, 2009.
• Narai S., Nagahata S. Effects of alendronate on the removal torque of implants in rats with in- duced osteoporosis. Int. J. Oral Maxillofac. Imp- lants. 18:218-223, 2003.
• Astrand J., Aspenberg P. Reduction of instability- induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop. Scand. 73:24-30, 2002.
• Eberhardt C., Schwarz M., Kurth A.H. High do- sage treatment of nitrogen-containing bisphosp- honate ibandronate is required for osseointegra- tion of cementless metal implants. J. Orthop. Sci. 10:622-626, 2005.
• Flichy-Fernández A., Balaguer-Martínez J., Peñarrocha-Diago M., Bagán J.V. Bisphospho- nates and dental implants: current problems. Med. Oral Patol. Oral Cir. Bucal. 14:E355-E60, 2009.
• American Association of Oral and Maxillofaci- al Surgeons Position Paper on Bisphosphonate- Related Osteonecrosis of the Jaws. J. Oral Maxil- lofac. Surg. 65:359-376, 2007.